. Perhaps the best drug resistance, and because of these defects chemostudied of these cellular responses is apoptosis, a physitherapy often fails. Understanding the molecular events ological cell death program that controls normal cell that contribute to drug-induced apoptosis, and how numbers during development and disease. We now untumors evade apoptotic death, provides a paradigm derstand many of the molecular events necessary for to explain the relationship between cancer genetics activation, amplification and execution of the apoptotic and treatment sensitivity and should enable a more ratioprocess, and it is evident that diverse drugs can kill nal approach to anticancer drug design and therapy.
. In fact, Bcl-2 was first identified based on its translocaal., 2001). In addition, p53 can transcriptionally activate both CD95 and TRAIL receptor 2 (TRAIL-R2/DR5), tion in follicular lymphoma, and is overexpressed in a variety of cancers (Reed, 1999 . Conversely, proapoptotic p53 may also have transcription-independent activities that potentiate cell death once the transcription-depenBcl-2 proteins are inactivated in certain cancers and disruption of these genes also promotes tumorigenesis dent functions initiate the process (Ryan et al., 2001). Therefore, it appears that p53 can function as a "master in mice (Table 1 ). In addition, mutations or altered expression of upstream regulators of Bcl-2 proteins are regulator" of the apoptotic program, capable of coordinating the process at multiple levels via several mechaassociated with cancer. For example, the Bad-kinase Akt, is positively regulated by various oncoproteins, and nisms. Still, p53 is not the only activator of the intrinsic apoptotic pathway. Some studies suggest that a related negatively regulated by the PTEN tumor suppressor (Datta et al., 1999) . Amplified Akt and mutated PTEN family member, p73, might substitute for p53 in certain circumstances (Yang and McKeon, 2000). Undoubtedly, have been found with high frequency in a variety of solid cancers, indicating the importance of this pathway in additional p53-independent activities are also important.
In addition to transcriptional regulation by p53, the regulating tumorigenesis (Table 1) . ). The potential apoptosis may not always result in a "lethal hit" to the for single drug resistance mechanisms to inhibit drug cell. Interestingly, the capacity of some tumor cells to action at multiple levels illustrates the complexity of the tolerate mitochondrial dysfunction may be because they problem. frequently express elevated levels of antioxidants (Volm, In summary, there is growing evidence that disruption 1998), and are often growing in glycolytic conditions and of apoptotic pathways contribute to drug resistance, therefore rely less on oxidative phosphorylation than with lesions upstream of mitochondrial damage producnormal cells (Dang and Semenza, 1999) . Thus, the longing the greatest effect. However, it is important to reterm survival of cells containing postmitochondrial demember that other drug-induced effects such as cytofects in apoptosis probably depends on several factors stasis and mitotic catastrophe can augment apoptosis including the intensity of the stimulus, the cellular conto help reduce the tumor burden. These additional eftext, and the physiological microenvironment. et al., 1999) . It has been argued Our discussion of apoptosis during tumor development that certain cell types require both the death receptor and mitochondrial pathways for drug-induced death, and following drug treatment reveals that these pro-cesses are remarkably similar. Thus, the very genetic rectly damage DNA. Whereas upstream drug resistance alterations that induce tumorigenesis can also mediate mechanisms such as P-gp overexpression prevent intrinsic resistance to both physiological (growth factor drug-induced damage, downstream resistance mechawithdrawal and hypoxia) and nonphysiological death nisms do not (Figure 1) . Hence, inhibition of apoptosis in stimuli (drugs). As a result, tumors that have never been drug resistant tumors not only affects the death-inducing challenged with drug can be inherently resistant to conactivities of the drug, but also allows for the possibility ventional chemotherapeutic agents. Put simply, these of cells acquiring additional mutations following DNA observations imply that tumor genotype is the most imdamage. In principle, these mutagenized cells could beportant parameter underpinning successful chemothercome more malignant and even less sensitive to subseapy using current drugs and regimes. This concept has quent therapies, such that treatment of highly resistant enormous implications for the future of cancer diagnosis tumors containing antiapoptotic lesions may be doing and treatment, for it suggests that more rational apmore harm than good. proaches to chemotherapy will require both an intimate At present there is no definitive proof that treatment knowledge of the genetic lesions that give rise to tumor of tumors harboring apoptotic lesions is deleterious. development, as well as a detailed understanding of the However, there is no doubt that the anticancer agents molecular basis of drug action.
Inhibition of Postmitochondrial Death Processes
can while another fails to demonstrate any significant effect attack. Each hurdle provides further selective pressure (Griffiths et al., 1997) . Both studies, however, show that to disable apoptosis, such that by the time a tumor p53 loss increases the survival of cells following DNA metastasizes, it is not surprising that it is highly resistant damage, and that these survivors harbor additional muto physiologic and pharmacologic death-inducing sigtations. Therefore, whether or not p53 affects the mutanals. This may explain, in part, why metastatic tumors tion rate directly, it clearly eliminates potentially mutated are notoriously chemoresistant (Fidler, 1999) . Indeed, cells. The possibility that cytotoxic drugs might actually the observations that metastatic tumors are enriched mutagenize tumors that cannot be killed highlights the for p53 mutations or overexpressed Bcl-2 support this necessity for a more rational approach for the future treatnotion (Sierra et al., 2000) . ment of cancer where the "cure matches the cause." What are the implications of these findings in terms of future treatment of cancer with cytotoxic drugs? If A More Rational Approach to Cancer Therapy inhibition of apoptosis is a necessary event for tumoriOur understanding of the molecular links between tugenesis and most chemotherapeutic drugs utilize intact morigenesis, apoptosis, and drug resistance provides apoptotic pathways to induce cell death, it is little wonthe foundation for a new age of targeted cancer therapy. der that drug resistance is such a major clinical problem.
For example, information concerning key apoptotic proWhile this may greatly impede our chances of successteins, their regulation, and the manner in which they are fully treating tumors with conventional drugs and treataltered in tumor cells can be used for target selection ment regimes, our increasing knowledge of the molecuin designing new anticancer agents. Alternatively, a lar links between tumorigenesis and apoptosis provides "blueprint" of the proteins and pathways necessary for new opportunities for a more tailored approach to chethe cytotoxic action of a given drug, coupled with an motherapy.
understanding of the molecular basis of drug resistance, may provide the necessary information to tailor existing The Potential Problem of Damage therapies for individual tumors. Although substantially without Cell Death more information is needed, both strategies are already Most conventional anticancer agents produce some form of cellular damage and, indeed, directly or indibeing pursued with promising results.
New Therapeutics such as hTERT can be reactivated by HDAC inhibitors, which might contribute to cellular immortalization and Although conventional agents were not designed to induce apoptosis, the fact that they do so indirectly demtumor progression (Takakura et al., 2001 ). Furthermore, HDAC inhibitors might reactivate imprinted genes which, onstrates that apoptosis can be an effective mechanism for eliminating tumor cells. In principle, agents that inin other settings, are associated with several human diseases, including cancer (Paulsen and Ferguson-Smith, duce apoptosis directly would overcome many of the problems observed with existing drugs and, as a result, 2001). As the mechanisms of gene silencing at specific loci are elucidated, it is possible that more specific strathave great therapeutic potential. Such an approach would have the following benefits. First, cell death is egies to reactivate discrete genes will be developed. Antisense approaches to decrease expression of a preferable to cytostasis, since tumor cells are eliminated and hence unable to contribute to tumor relapse. Secwide variety of antiapoptotic genes including Bcl-2, Ras, X-IAP, and Mdm2 are in various stages of preclinical ond, apoptosis is preferable to necrosis, since it is a particularly efficient mode of cell death that does not development ( Although large-scale genotyping of tumors is still Most conventional anticancer agents were selected years from the clinic, the use of drug-resistance markers based on their ability to selectively kill tumor cells at to tailor cancer therapy has already been applied in a clinically achievable doses. This tumor specificity has more simplistic manner. For example, leukemias that been attributed to the increased proliferation rate of acquire drug resistance after an initial round of therapy cancer cells, but this is almost certainly not a sufficient are often screened for the presence of P-gp. If P-gp explanation. Instead, the answer may return to the nois found to be expressed in the resistant tumors, new tion that many cells possess mechanisms that couple therapeutic regimes using drugs that are not P-gp subinappropriate cell division to apoptosis. While some destrates, or combination therapies involving P-gp inhibigree of apoptosis inhibition must accompany tumoritors, are used. The recent findings that P-gp can both genesis, it is clear that tumor cell survival reflects a fine efflux chemotherapeutic drugs and inhibit caspase actibalance between hyperproliferative, proapoptotic, and vation could lead to a further alteration to the criteria antiapoptotic events. Thus, the addition of yet another for selecting drugs capable of killing P-gp expressing apoptotic stimulus in the form of a chemotherapeutic tumors ( . It now appears that drug toxicity is due, in part, hances its ability to induce apoptosis (Krek et al., 1995) .
to apoptosis induced by p53. Hence, p53 Ϫ/Ϫ mice treated Therefore, inhibition of cyclinA/cdk2 binding to E2F-1 with chemotherapeutic drugs or radiotherapy do not in cells containing inactive pRb would result in activation suffer the same degree of damage in susceptible tisof E2F-1 and induction of apoptosis. This hypothesis sues, and can survive doses that are lethal for wild-type was tested using soluble peptides that block the interacanimals (Komarova and Gudkov, 2000). This apparently tion of cyclinA/cdk2 with E2F-1. Apoptosis was readily results from disruption of the intrinsic apoptotic pathway induced in tumor cells with inactivated pRb but not in since ectopic expression of Bcl-2 in bone marrow cells normal cells, demonstrating the potential for rationally achieves a similar effect (Domen et al., 1998). Impordesigned agents (Chen et al., 1999) .
tantly, there is a direct correlation between p53 activaTailoring Cancer Therapy tion and the sites of normal tissue toxicity (Komarova A variation on the theme of rational drug design is the and Gudkov, 2001). These studies highlight the reasons idea of individualized therapy whereby the "cure circumunderlying the general lack of success in developing vents the cause." Theoretically, a more targeted apdrugs that can specifically kill target cells using an emproach to chemotherapy might involve genotyping indipirical approach. On one hand, p53 potentiates the acvidual tumors for their drug resistance profiles, and then tion of most drugs but is functionally inactivated in most employing agents known to work effectively despite the tumors. On the other hand, an intact p53 pathway in identified antiapoptotic lesions. The potential of this apnormal cells contributes to their own destruction. proach is illustrated by a study demonstrating that tumor
In theory, it should be possible to reduce the "collatcells with elevated levels of c-myc and wild-type p53 are selectively sensitive to 5-FU (Arango et al., 2001) .
eral damage" that gives rise to the side effects of chemo-
